"We reiterate our Buy rating and $30 target. We highlight that we currently omit the 38 undisclosed partnered assets at the company, and look to provide potential contribution once identification and terms are delineated. Further, we do not include valuation contribution from projected cash flow from expected milestone payments from partners. Our clinical NPV model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
The recent report surprised many as the company turned a $3.8 million loss in 2018 to a $1.88 million profit in the first quarter, the stock has had a considerable jump in recent days but there is plenty of gains still to be had.
Analyst average rating Overweight
Analysts Price target $27.50
Short Interest 17%
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab.
Sign Up for our 100% Free Email Newsletter:
Text Message Alerts ---> text 'PS101' to 67076
(It's FREE, however Msg&Data rates may apply.)